These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7517835)

  • 1. Efficacy and safety of fluvastatin, a new HMG CoA reductase inhibitor, in elderly hypercholesterolaemic women.
    Baggio G; De Candia O; Forte PL; Mello F; Andriolli A; Donazzan S; Valerio G; Milani M; Crepaldi G
    Drugs; 1994; 47 Suppl 2():59-63. PubMed ID: 7517835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
    Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fluvastatin in the treatment of hyperlipoproteinemia, initial experience].
    Ceska R
    Vnitr Lek; 1996 Aug; 42(8):533-6. PubMed ID: 8967021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia.
    Koizumi J; Haraki T; Yagi K; Inazu A; Kajinami K; Miyamoto S; Ueda K; Ohta M; Takegoshi T; Takeda M
    Am J Cardiol; 1995 Jul; 76(2):47A-50A. PubMed ID: 7604797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
    Greten H; Beil FU; Schneider J; Weisweiler P; Armstrong VW; Keller C; Klör HU; von Hodenberg E; Weidinger G; Eskötter H
    Am J Med; 1994 Jun; 96(6A):55S-63S. PubMed ID: 8017468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
    Leitersdorf E; Eisenberg S; Eliav O; Friedlander Y; Berkman N; Dann EJ; Landsberger D; Sehayek E; Meiner V; Wurm M
    Circulation; 1993 Apr; 87(4 Suppl):III35-44. PubMed ID: 8462179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
    Leitersdorf E; Muratti EN; Eliav O; Peters TK
    Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia.
    Knopp RH; Frohlich J; Jokubaitis LA; Dawson K; Broyles FE; Gomez-Coronado D
    Am J Med; 1994 Jun; 96(6A):69S-78S. PubMed ID: 8017470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
    Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G
    Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia.
    Tomlinson B; Mak TW; Tsui JY; Woo J; Shek CC; Critchley JA; Masarei JR
    Am J Cardiol; 1995 Jul; 76(2):136A-139A. PubMed ID: 7604789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
    Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
    Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.
    Zavoral JH; Haggerty BJ; Winick AG; Bergmann SD
    Am J Cardiol; 1995 Jul; 76(2):37A-40A. PubMed ID: 7604795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
    Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J
    Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
    Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
    Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin.
    Lye M; Valacio R; Reckless JP; Ghosh AK; Findlay IN; Ghosh MK; Passmore AP; Fulcher RA
    Coron Artery Dis; 1998; 9(9):583-90. PubMed ID: 9861520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin.
    Smit JW; Wijnne HJ; Schobben F; Sitsen A; de Bruin TW; Erkelens DW
    Am J Cardiol; 1995 Jul; 76(2):89A-96A. PubMed ID: 7604808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia.
    Leitersdorf E; Eisenberg S; Eliav O; Berkman N; Dann EJ; Landsberger D; Sehayek E; Meiner V; Peters TK; Muratti EN
    Eur J Clin Pharmacol; 1993; 45(6):513-8. PubMed ID: 8157036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients.
    Teramoto T; Goto Y; Kurokawa K; Nakamura H; Yoshida S; Saito Y; Nakaya N; Itakura H; Takaku F; Yamada N
    Am J Cardiol; 1995 Jul; 76(2):33A-36A. PubMed ID: 7604794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluvastatin reduces levels of plasma apo B-containing particles and increases those of LpA-I. European Fluvastatin Study Group.
    Dallongeville J; Fruchart JC; Pfister P; Bard JM
    Am J Med; 1994 Jun; 96(6A):32S-36S. PubMed ID: 8017464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol.
    Sasaki S; Nakagawa M; Nakata T; Endo N; Miyao K; Kitamura K; Fukuyama M; Kitani T; Yamada C
    Cardiology; 1997; 88(2):160-5. PubMed ID: 9096917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.